Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761676 | 0.95 | ACHE (0.52) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL8250709 | 0.89 | ACHE (0.44) | ACHEBACE1PDE10AENPP1AURKA | |
| Formic Acid SCHEMBL5471549 | 0.88 | ACHE (0.47) | ACHEBACE1ENPP1AURKAPDGFRB | |
| SCHEMBL8247275 | 0.86 | ACHE (0.53) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL4760323 | 0.85 | ACHE (0.52) | ACHEBACE1PDE10AENPP1AURKA | |
| Formic Acid SCHEMBL5470498 | 0.84 | ACHE (0.46) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL4761702 | 0.84 | ACHE (0.50) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL4760245 | 0.82 | MAPK1 (0.55) | ACHEBACE1PDE10AENPP1AURKA | |
| Trifluoroacetic Acid SCHEMBL4760864 | 0.82 | ACHE (0.48) | ACHEBACE1PDE10AENPP1AURKA | |
| SCHEMBL4760867 | 0.81 | ACHE (0.47) | ACHEBACE1PDE10AENPP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | claimed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | claimed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | ACHE 66/4885BACE1 707/4885PDE10A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.